L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension
|
|
- Poppy Todd
- 5 years ago
- Views:
Transcription
1 Clin Auton Res (8) 8[Suppl ]:5 9 DOI.7/s z ARTICLE Christopher J. Mathias L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension The European experience Received: 5 October 7 Accepted: 6 November 7 Prof. C.J. Mathias, DPhil, DSc, FRCP, FMedSci Neurovascular Medicine Unit Faculty of Medicine Imperial College London at St Mary s Hospital Praed Street London W NY, UK Tel.: +44-7/ Fax: +44-8/ c.mathias@imperial.ac.uk C.J. Mathias, DPhil, DSc, FRCP, FMedSci (&) Autonomic Unit National Hospital for Neurology and Neurosurgery Institute of Neurology University College London London, WCIN 3 BG, UK j Abstract Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a major management problem in disorders such as pure autonomic failure, multiple system atrophy and also in Parkinson s disease. Treatment is ideally two pronged, using non-pharmacological and pharmacological measures. Drug treatment ideally is aimed at restoring adequate amounts of the neurotransmitter noradrenaline. This often is not achievable because of damage to sympathetic nerve terminals, to autonomic ganglia or to central autonomic networks. An alternative is the use of sympathomimetics (that mimic the effects of noradrenaline, but are not identical to noradrenaline), in addition to other agents that target physiological mechanisms that contribute to blood pressure control. L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. Experience in Caucasians and in Europe is limited mainly to patients with dopamine beta hydroxylase deficiency. This review focuses on two studies performed in Europe, and provides information on its efficacy, tolerability and safety in patients with pure autonomic failure, multiple system atrophy and Parkinson s disease. It also addresses the issue of whether addition of dopa decarboxylase inhibitors, when combined with l-dopa in the treatment of the motor deficit in Parkinson s disease, impairs the pressor efficacy of Droxidopa. j Key words l-dihydroxyphenylserine Æ orthostatic hypotension Æ autonomic failure Æ noradrenaline Æ multiple system atrophy Æ Parkinson s disease CAR 5
2 6 Introduction Orthostatic (or postural) hypotension (OH) is a cardinal manifestation of generalised autonomic failure and often is the presenting feature in patients with primary autonomic failure due to pure autonomic failure (PAF) and multiple system atrophy (MSA) [9]. It is increasingly recognised also in Parkinson s disease []. It results in a number of symptoms, mainly as a result of hypoperfusion of organs, including the skeletal musculature. Organs above the level of the heart, such as the brain, are particularly susceptible to hypoperfusion; this can result in dizziness, visual disturbances, cognitive deficits and loss of consciousness [, 6]. Orthostatic hypotension can reduce mobility, result in falls, and may cause trauma and injuries, at times with devastating effects including death. The symptomatic consequences of OH, taken together can substantially reduce a patients quality of life. There are many causes of OH that can be considered under the mechanisms responsible - neurogenic, non-neurogenic and drug induced []. Non-neurogenic OH is rectified more readily than neurogenic OH, which often is difficult to treat, with management dependent on a combination of non-pharmacological measures and drugs [3, ]. A key factor in neurogenic OH is reduction in sympathetic nerve activity, and thus a reduction of the neurotransmitter, noradrenaline at the synaptic cleft. To replace this deficiency a variety of drugs that mimic noradrenaline have been used, that include ephedrine and midodrine, which are of partial benefit and have limitations to their use because of adverse effects. The ideal approach would be replacement of noradrenaline itself. L-threo-dihydroxyphenylserine (Droxidopa) has a structure which is similar to noradrenaline but with a carboxyl group. It can be administered orally, and is acted upon by the ubiquitous enzyme L-aromatic amino acid decarboxylase (dopa decarboxylase), which is found all over the body. It is converted directly to noradrenaline. It is likely to have both neuronal and extra neuronal effects, with a direct effect through noradrenaline on target organs. Droxidopa has been highly successful in replacing deficient or absent noradrenaline in patients with dopamine beta hydroxylase deficiency [4, 5, 5]. In Japan, it has been approved since 989 use for in the treatment of neurogenic OH due to various disorders, that include familial amyloid polyneuropathy, haemodialysis induced hypotension, and MSA and PD [8, 4, 6, 7, 8]. Experience with Droxidopa, especially in primary autonomic failure and PD in Caucasians is limited. Because of its potential value in the management of symptomatic orthostatic hypotension, two Phase II studies were performed in Europe. These were multicentre, multinational studies. An escalating dose of Droxidopa was used in the first study in patients with PAF and MSA. In the second a randomised double blind placebo controlled study was performed using three doses of Droxidopa in patients with MSA or PD. This review will describe key components from each of these studies, and will focus on whether inhibition of the enzyme dopa decarboxylase, which converts Droxidopa to noradrenaline, can influence its ability to reduce orthostatic hypotension. Droxidopa in pure autonomic failure and multiple system atrophy This study was performed in 6 PAF and 6 MSA patients with symptomatic orthostatic hypotension [7]. It was an open dose ranging study with a one week run in period, following which three doses of Droxidopa,, and 3 mg were administered twice daily. The incremental dose adjustment was dependent on the blood pressure response and an improvement in symptoms. When optimum dosage was reached the dosage was maintained for a 6 week period. The study therefore determined both the efficacy and the tolerability of increasing doses of Droxidopa in treating symptomatic orthostatic hypotension in PAF and MSA. This dose escalating trial was performed in ten centres within three countries in Europe. A key primary variable was to determine the extent of decrease in orthostatic fall in systolic blood pressure. Table provides details of the response to Droxidopa. The effects of Droxidopa persisted even at the last individual visit, with orthostatic systolic blood pressure reductions of, 9 and 3 mmhg respectively. In 5 patients (78%) OH had improved, and in 4 (44%) OH was not measurable. Importantly the mean supine systolic BP levels were not elevated (Table ). Thus Droxidopa, particularly in the highest doses, was efficacious in reducing OH (Fig. ). In this study, symptoms associated with orthostatic hypotension, that included light headedness, dizziness and blurred vision were assessed while on and when off Droxidopa drug. These were evaluated using bi-polar scales with ten point numeric objectivity. They showed an improvement in both objective and subjective evaluations of benefit (Fig. ). Droxidopa was well tolerated. There were two serious adverse events; laryngeal dyspnoea and syncope. The first was on mg twice daily and the second on 3 mg twice daily. Both could be attributed to the disease itself rather than to the drug. Supine hypertension was not reported.
3 7 Table Dose effects of L-threo-DOPS (Droxidopa) expressed as change from baseline, in multiple system and pure antonomic failure patients. L-threo-DOPS dose mg twice daily mg twice daily 3 mg twice daily Last individual visit per dose* n=3* n=5* n=7* Baseline orthostatic SBP decrease 54.3 ± ± ± 4.9 Final visit supine SBP.9 ± ± ± 3.9 Reduction in orthostatic SBP decrease )3. ± 8. )8.4 ± 54.4 ).7 ± 36.4 Reduction in orthostatic DBP decrease )9.4 ± 7. ).9 ± 3. ).5 ±.6 Noradrenaline while supine 56.5 ±,4. (n = 3) ±,4. (n = 3) 966. ± (n = 4) Noradrenaline at end of standing period,96.8 ±,8.8,35. ±,6.4,36.9 ± (n = 6) Last individual visit* n =7* n =8* n = 7* Baseline orthostatic SBP decrease 48.7 ± ±. 6.6 ± 4.9 Final visit supine SBP 9.3 ± ± ± 3.9 Reduction in orthostatic SBP decrease )9.7 ± 3.9 )8.5 ±. ).7 ± 36.4 Reduction in orthostatic DBP decrease )9. ± 8.8 )5. ± 8.6 ).5 ±.6 Noradrenaline while supine 47. ± ± (n = 7) 966. ± (n = 4) Noradrenaline at end of standing period,34.6 ±,77.5,33.5 ±,659.8,36.9 ± (n = 6) Analysis used all available data, with n values as shown in asterisked (*) rows unless otherwise specified against mean values. Orthostatic blood pressure decrease data were obtained after 5 min standing and are measured in mm Hg. Noradrenaline plasma concentration are pg/ml Data for noradrenaline at end of standing time represent actual values and are not presented as change from baseline SBP = systolic blood pressure; DBP = diastolic blood pressure From: Mathias CJ, Senard J-M, Braune S, Watson L, Aragishi A, Keeling J, Taylor M. L-threo-dihydroxphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-centre, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Aut Res, ; In summary, Droxidopa was an effective drug which reduced the orthostatic fall in blood pressure in patients with PAF and MSA. It improved symptoms of OH and was well tolerated. It did not result in supine hypertension. The most effective of the three tested doses was 3 mg twice daily. Orthostatic BP fall at last visit (mmhg) Deterioration Improvement MSA Orthostatic BP fall at baseline (mmhg) Fig. Orthostatic systolic blood pressure decrease at baseline and at individual last visit. Individual orthostatic blood pressure decrease (mm Hg) after 5-minuties standing at last visit is plotted against decrease at baseline (all 3 efficacyevaluable patients). Each point below the line represents a patient whose condition improved between baseline and last visit, and every point above this line a patient whose condition deteriorated. From: Mathias CJ, Senard J-M, Braune S, Watson L, Aragishi A, Keeling J, Taylor M. L-threo-dihydroxphenylserine (Lthreo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-centre, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Aut Res, ; PAF Droxidopa in multiple system atrophy and in Parkinson s disease This study was designed to determine the minimum effective dose of Droxidopa that safely reduced the orthostatic fall in systolic blood pressure in comparison with placebo. After screening and evaluation a total of patients with either MSA or PD were randomized and received doses of,, 3 mg of Droxidopa or matching placebo. The drug was administered three times daily, as was placebo. It was conducted in 3 centres within 4 European countries. The screening period was between two seven days and the treatment continued for 8 days. Data was obtained in 55 patients with MSA and in 66 with Parkinson s disease. A preliminary report recently has been presented [3]. Droxidopa treatment resulted in a reduction in the orthostatic fall in blood pressure with each of the Droxidopa doses, unlike with placebo. It was noted that in the previous study the same patient had escalating doses with individual comparisons, unlike this second study with different individuals on different doses of drugs. There was no clear dose response improvement but the 3 mg dose was the
4 8 Fig. Transition table for the symptom Lightheadedness. Dizziness Analysis group: Overall, N = 3. ( = not at all, = very severe). Each * represents one patient (p =.5). From: Mathias CJ, Senard J-M, Braune S, Watson L, Aragishi A, Keeling J, Taylor M. L-threodihydroxphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-centre, doseranging study in multiple system atrophy and pure autonomic failure. Clin Aut Res, ; Score after Treatment Baseline Score All Deterioration Improvement All most effective in reducing OH. Even with this dose mean levels of supine blood pressure were not elevated after acute or chronic dosage. The drug remained efficacious 8 days of treatment. In this study up to 9mg of Droxidopa was used each day, and adverse effects on heart rate were analysed. There was neither bradycardia nor tachycardia with any of the doses, at day or after 8 days of treatment. The majority of patients in this study had mild to moderate symptoms of dizziness, tiredness and visual disturbance. There was no loss of consciousness before or after drug or placebo treatment. There was an overall trend towards improvement in symptoms but this did not reach statistical significance. The reasons for the apparent dissociation between objective improvement in OH and subjective reduction in symptoms remains unclear. It may reflect the different individual characteristics of each group, or insensitivity of the symptom scales used. Droxidopa was well tolerated, with similar adverse effects in each of the treatment groups when compared with placebo. Most of the symptoms were mild. One patient had supine hypertension. In summary, therefore, 3 mg tid of Droxidopa was more effective than either or mg in the majority of patients with MSA or PD. It was well tolerated and with few side effects. Droxidopa in patients on dopa decarboxylase inhibitors Dopa decarboxylase is essential for the conversion of Droxidopa into noradrenaline and would be expected noradrenaline to reduce the formation of a dopa decarboxylase inhibitor and thus the prodrugs pressor effect. In each of the studies described there were patients treated with a combination of L-dopa and dopa decarboxylase inhibitors. In the first study these included MSA patients, and in the second both MSA and PD patients. There were no obvious differences in the beneficial response of Droxidopa in the first study with patients on a dopa decarboxylase inhibitor. Similar observations were made in the second study, where over 8% of the PD patients were on a dopa decarboxylase inhibitor. In a previous study in 4 PAF and MSA patients, pre-treatment with mg of the dopa decarboxylase inhibitor Carbidopa, prior to Droxidopa, blunted the pressor effects of Droxidopa []. Plasma noradrenaline levels rose from 94 ± 8 to 86 ± 35 pg/ml in Droxidopa treated patients compared to 6 ± 5 to 47 ± 7 after Droxidopa treated patients had been pretreated with Carbidopa, which thus attenuated, but did not abolish, the rise in levels of plasma noradrenaline. It is important to note that the dose of carbidopa used in this study [] was substantially higher than the dose used in clinical preparations when combined with l-dopa, these usually being 5mg for mg of l-dopa. In each of the European studies reported there was a beneficial pressor effect of Droxidopa despite the presence of a dopa decarboxylase inhibitor; this may reflect incomplete inhibition of dopa decarboxylase with the clinical preparations used to treat the motor deficits. The pressor effect may even have been higher without an inhibitor. Conclusions Treatment with Droxidopa, which results in the formation of noradrenaline, has been demonstrated
5 9 in two pan European studies to be effective, well tolerated and safe when used to treat orthostatic hypotension in patients with pure autonomic failure, multiple system atrophy, and Parkinson s disease. j Acknowledgements Major investigators have included Professor P Cortelli, Professor J M Senard, and many colleagues in participating centres. Disclosure Prof. C.J. Mathias was the Principal Investigator of both studies reviewed, which were supported by Sumitomo Pharmaceuticals, Japan. He is a Consultant for Chelsea Therapeutics, USA. References. Heims HC, Martin NH, Critchley HD, Jäger HR, Mathias CJ, Cipolotti L. (6). Cognitive functioning in orthostatic hypotension due to pure autonomic failure. Clin Aut Res 6:3. Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R. (3) Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 8: Lahrmann H, Cortelli, Hilz M, Mathias CJ, Struhal W, Tassinari M. (6) European Federation of Neurological Society guidelines on the diagnosis and management of orthostatic hypotension. Europ J Neurol 3: Man in t Veld AJ, Van den Meiracker AH, Boomsma F, Schalekamp MADH. (987) Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine beta-hydroxylase deficiency. Lancet ii: Mathias CJ, Bannister R, Cortelli P, Heslop K. Polak J, Raimbach SJ, Springall DB, Watson L. (99) Clinical autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta-hydroxylase. QJM, New Series 75(78): Mathias CJ, Mallipeddi R, Bleasdale- Barr K. (999) Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J Neurol 46(): Mathias CJ, Senard J-M, Braune S, Watson L, Aragishi A, Keeling J, Taylor M. () L-threo-dihydroxphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multicentre, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Aut Res : Mathias CJ, Bannister R. () Dopamine beta-hydroxylase deficiency. In: Mathias CJ, Bannister R, (eds.) Autonomic failure. A textbook of clinical disorders of the autonomic nervous system. 4th ed. Oxford and New York: Oxford University Press pp Mathias CJ. (3) Autonomic diseases clinical features and laboratory evaluation. JNNP 74:3 4. Mathias CJ. (3) Autonomic diseases Management. JNNP 74:4 47. Mathias CJ. (5) Cardiovascular Autonomic Dysfunction in Parkinson s Disease and Parkinsonian Syndromes. In: Ebadi M, Pfeiffer RF. (Eds.) Parkinson s Disease. CRC Press LLC, New York Mathias CJ. (6) Orthostatic hypotension and orthostatic intolerance. In: DeGroot LJ, Jameson JL, de Kretser D, Grossman AB, Marshall JC, Melmed S, Potts JT, Weir GC. (Eds.) Endocrinology. 5th edition. Elsevier Saunders, Philadelphia PA, USA Mathias CJ, Senard JM, Cortelli P. (7) A double-blind, randomized, placebo-controlled study to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension associated with multiple system atrophy or Parkinson s disease. Clin Aut Res 7:7. abstract 4. Narabayashi H, Nakanishi T. (987) Therapeutic effects of L-DOPS in Parkinson s disease, double-blind comparative study against placebo as control in patients with long-term levodopa therapy. Clin Eva 5: Robertson D, Goldberg MR, Onrot J, Hollister AS, Wiley R, Thompson JG, Robertson RM. (987) Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine New Engl. J. Med 34: Sobue I, Senda Y, Hirayama K, et al. (987) Clinical pharmacological evaluation of L-threo-3-4-dihydroxyphenylserine (L-DOPS) in Shy-Drager s syndrome and its related diseases. A nationwide double-blind comparative study. Jpn J Clin Exp Med 4: Suzuki T, Higa S, Sakoda S, et al. (98) Pharmacokinetic studies of oral L- threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy. Eur J Clin Pharmacol 3: Yanagisawa N, Ikeda S, Hashimoto T, Hanyu N, Nakagawa S, Fujimori N, Ushiyama M. (998) Effects of L-threo- Dops on orthostatic hypotension in Parkinson s disease. No To Shinkei 5:57 63
L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension
Clin Auton Res (2008) 18[Suppl 1]:19 24 DOI 10.1007/s10286-007-1002-2 ARTICLE Horacio Kaufmann L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension The US experience
More informationNeurogenic orthostatic hypotension (NOH) results from
Norepinephrine Precursor Therapy in Neurogenic Orthostatic Hypotension Horacio Kaufmann, MD; Daniela Saadia, MD; Andrei Voustianiouk, PhD; David S. Goldstein, MD, PhD; Courtney Holmes, CMT; Melvin D. Yahr,
More informationNorthera (droxidopa)
Northera (droxidopa) Policy Number: 5.01.657 Last Review: 07/2018 Origination: 07/2018 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Northera
More informationORTHOSTATIC INTOLERANCE AN EXPRESSION OF AUTONOMIC DISFUNCTION IN PARKINSON S DISEASE
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2014 vol. 118, no. 1 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS ORTHOSTATIC INTOLERANCE AN EXPRESSION OF AUTONOMIC DISFUNCTION IN PARKINSON S DISEASE Emilia-Lidia
More informationdroxidopa (Northera )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information6/13/2017 PROFESSOR CHRISTOPHER J MATHIAS. Non-motor features in PD AUTONOMIC NERVOUS SYSTEM. Motor. Non-Motor CLINICAL AUTONOMIC MANIFESTATIONS
PRFESSR CRISTPER J MATIAS Autonomic & Neurovascular Medicine Centre and The Joint ypermobility Unit, ospital of St John & St Elizabeth, St Johns Wood, London Autonomic Dysfunction in Parkinsons Disease:
More informationTreatment of orthostatic hypotension in Multiple System Atrophy New Clinical Studies
Treatment of orthostatic hypotension in Multiple System Atrophy New Clinical Studies Cyndya A. Shibao, M.D., F.A.H.A. Assistant Professor of Medicine Division of Clinical Pharmacology Disclosure Lundbeck
More informationContempo GIMSI Cosa cambia alla luce della letteratura in tema di terapia farmacologica
Contempo GIMSI 2015-2017 Cosa cambia alla luce della letteratura in tema di terapia farmacologica Dott.ssa Diana Solari Centro Aritmologico e Sincope Unit, Lavagna www.gimsi.it POST 2 (Prevention of Syncope
More informationExercise hemodynamics in Parkinson s Disease and autonomic dysfunction
Exercise hemodynamics in Parkinson s Disease and autonomic dysfunction David A. Low 1,2,3*, Ekawat Vichayanrat 2,3, Valeria Iodice 2,3 and Christopher J. Mathias 2,3 1 Research Institute of Sport and Exercise
More informationI ngestion of water increases seated blood pressure (BP) in
1737 PAPER The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure T M Young, C J Mathias... See end of
More informationDr. David Robertson Elton Yates Professor of Autonomic Disorders Professor of Medicine, Pharmacology and Neurology Vanderbilt University April 2007
Dr. David Robertson Elton Yates Professor of Autonomic Disorders Professor of Medicine, Pharmacology and Neurology Vanderbilt University April 2007 Pathophysiology and Diagnosis of Orthostatic Hypotension
More informationNORTHERA (droxidopa) oral capsule
NORTHERA (droxidopa) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationDiagnosing and Treating Neurogenic Orthostatic Hypotension: A Case Study
Diagnosing and Treating Neurogenic Orthostatic Hypotension: A Case Study Learning Objectives: Illustrate how to accurately diagnose noh Employ scales and questionnaires in combination with cardiovascular
More informationNew Drug Evaluation: droxidopa capsules, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNorthera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension. September 2010
Northera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension September 2010 1 2004-2010 Chelsea Therapeutics, Inc. This presentation is being provided for
More informationIntegrated analysis of droxidopa trials for neurogenic orthostatic hypotension
Biaggioni et al. BMC Neurology (2017) 17:90 DOI 10.1186/s12883-017-0867-5 RESEARCH ARTICLE Open Access Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension Italo Biaggioni 1*,
More informationComparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects
Drugs R D (2018) 18:77 86 https://doi.org/10.1007/s40268-018-0226-z ORIGINAL RESEARCH ARTICLE Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily
More information:{ic0fp'16. Geriatric Medicine: Blood Pressure Monitoring in the Elderly. Terrie Ginsberg, DO, FACOI
:{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Geriatric Medicine: Blood Pressure Monitoring in the Elderly Terrie Ginsberg, DO, FACOI Blood Pressure Management in the Elderly Terrie B.
More informationNeurogenic Orthostatic Hypotension: Expert Perspectives on Diagnosis and Treatment Strategies CME
Neurogenic Orthostatic Hypotension: Expert Perspectives on Diagnosis and Treatment Strategies CME Supported by an independent educational grant from Lundbeck, Inc. www.medscape.org/roundtable/neurogenic-orthostatic-hypotension
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Northera) Reference Number: CP.PMN.17 Effective Date: 08.01.16 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationCARDIOVASCULAR DYSFUNCTION IN PARKINSONIAN DISORDERS
CARDIOVASCULAR DYSFUNCTION IN PARKINSONIAN DISORDERS Christopher J. Mathias Neurovascular Medicine Unit, Division of Neuroscience & Psychological Medicine, Imperial College School of Medicine at St Mary
More informationSubject: Northera (droxidopa) Original Effective Date: 7/10/2018. Policy Number: MCP-313. Revision Date(s): Review Date: MCPC Approval Date: 7/10/2018
Subject: Northera (droxidopa) Original Effective Date: 7/10/2018 Policy Number: MCP-313 Revision Date(s): Review Date: MCPC Approval Date: 7/10/2018 DISCLAIMER This Molina Clinical Policy (MCP) is intended
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More informationExercise Training for PoTS and Syncope
B 140 120 100 80 60 40 20 0 Blood Pressure (mm Hg) Blood Pressure Heart Rate 60 degree Head Up Tilt Time 140 120 100 80 60 40 20 0 Heart Rate (beats.min -1 ) Exercise Training for PoTS and Syncope C Blood
More informationPremotor PD: autonomic failure
Premotor PD: autonomic failure Division of Neurobiology Department of Neurology Medical University of Innsbruck Non-motor symptoms in PD Autonomic OH, constipation, impotence, urinary incontinence or retention,
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Adamec I., Klepac N., Milivojević I., Radić B., Habek M. (2012) Sick sinus syndrome and orthostatic hypotension in Parkinson's disease. Acta Neurologica Belgica, 112 (3).
More informationFindings from the 2015 HRS Expert Consensus Document on Postural Tachycardia Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST)
Findings from the 2015 HRS Expert Consensus Document on Postural Tachycardia Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST) Ahmad Hersi, MBBS, MSc, FRCPC Professor of Cardiac Sciences Consultant
More informationBlood pressure fluctuation and hypertension in patients with Parkinson s disease
Blood pressure fluctuation and hypertension in patients with Parkinson s disease Tetsuro Tsukamoto 1, Yoshimi Kitano 2 & Sadako Kuno 3 1 Department of Neurology, Numazu Rehabilitation Hospital, 2510-22
More informationDroxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson s Disease (NOH306A)
Journal of Parkinson s Disease 4 (2014) 57 65 DOI 10.3233/JPD-130259 IOS Press Research Report 57 Droxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson s Disease (NOH306A)
More informationDizziness, postural hypotension and postural blackouts: Two cases suggesting multiple system atrophy
Dizziness, postural hypotension and postural blackouts: Two cases suggesting multiple system atrophy Dr Rahul Chakor, Associate Prof and Head Dept of Neurology, Dr Anand Soni, Senior Resident, T N Medical
More informationClinical Studies 129
Clinical Studies 129 Syncope in migraine. The population-based CAMERA study Roland D. Thijs, 1* Mark C. Kruit, 2* Mark A. van Buchem, 2 Michel D. Ferrari, 1 Lenore J. Launer, 3,4 and J. Gert van Dijk
More informationThe Movement Disorders Task Force Review of Dysautonomia Rating Scales in Parkinson s Disease with Regard to Symptoms of Orthostatic Hypotension
REVIEW The Movement Disorders Task Force Review of Dysautonomia Rating Scales in Parkinson s Disease with Regard to Symptoms of Orthostatic Hypotension Anne Pavy-Le Traon, MD, PhD, 1 * Gerard Amarenco,
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationIntegrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease
CLINICAL PRACTICE Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease Robert A. Hauser, MD, MBA, 1, * Italo Biaggioni, MD, 2 L. Arthur
More informationSistema Nervoso Vegetativo Vademecum per la diagnosi differenziale
Sistema Nervoso Vegetativo Vademecum per la diagnosi differenziale Pietro Cortelli IRCCS Istituto delle Scienze Neurologiche di Bologna DIBINEM, Alma Mater Studiorum - Università di Bologna Anatomo-Functional
More informationF indings or symptoms of autonomic dysfunction are
1407 PAPER Age and duration related changes in muscle sympathetic nerve activity in Parkinson s disease K Shindo, H Watanabe, H Tanaka, K Ohashi, T Nagasaka, S Tsunoda, Z Shiozawa... See end of article
More informationTreatments for Dysautonomias
Treatments for Dysautonomias Successful treatment of dysautonomias usually requires an individualized program, which can change over time. You should understand that since the underlying mechanisms often
More information1. INTRODUCTION. National Hospital for Neurology & Neurosurgery, London
RATE OF CHANGE IN CEREBRAL OXYGENATION AND BLOOD PRESSURE IN RESPONSE TO PASSIVE CHANGES IN POSTURE: A COMPARISON BETWEEN PURE AUTONOMIC FAILURE PATIENTS AND CONTROLS Ilias Tachtsidis, Clare E. Elwell,
More informationAutonomic Variation of Blood Pressure in Middle Aged Diabetics: A Prospective Study
Original Article DOI: 10.17354/ijss/2016/16 Autonomic Variation of Blood Pressure in Middle Aged Diabetics: A Prospective Study M Usharani 1, K Chandini 2 1 Professor and Head, Department of Physiology,
More informationIntroduction. William Smith 1 Hong Wan. Patrick Martin 2,4
Clin Auton Res (2016) 26:269 277 DOI 10.1007/s10286-016-0363-9 RESEARCH ARTICLE Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled,
More informationHow To Manage Autonomic Symptoms in Multiple System Atrophy. Amanda C. Peltier, MD MS Neurology
How To Manage Autonomic Symptoms in Multiple System Atrophy Amanda C. Peltier, MD MS Neurology Disclosures NIH Autonomic Rare Diseases Consortium Checking your blood pressure several times a day is helpful
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationClinical Study Nondipping in Parkinson s Disease
SAGE-Hindawi Access to Research Parkinson s Disease Volume 2011, Article ID 897586, 5 pages doi:10.4061/2011/897586 Clinical Study Nondipping in Parkinson s Disease Sita Sommer, 1 Billur Aral-Becher, 1
More informationWhat you need to know as you begin your treatment for symptomatic neurogenic orthostatic hypotension (noh)
SEE IF YOU CAN BREAK FREE WITH NORTHERA (droxidopa) What you need to know as you begin your treatment for symptomatic neurogenic orthostatic hypotension (noh) Use NORTHERA (droxidopa) is a prescription
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationThe Legacy of Dr. David Robertson Diagnosis and Treatment of Autonomic Disorders
The Legacy of Dr. David Robertson Diagnosis and Treatment of Autonomic Disorders May 3-4, 2018 David Robertson, M.D. Elton Yates Professor of Medicine, Pharmacology & Neurology Vanderbilt University Medical
More informationP ure autonomic failure (PAF) is a sporadic idiopathic
PAPER Progression and prognosis in pure autonomic failure (): comparison with multiple system atrophy N Mabuchi, M Hirayama, Y Koike, H Watanabe, H Ito, R Kobayashi, K Hamada, G Sobue... See end of article
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationEvidence-based treatment of neurogenic orthostatic hypotension and related symptoms
J Neural Transm (2017) 124:1567 1605 DOI 10.1007/s00702-017-1791-y HIGH IMPACT REVIEW IN NEUROSCIENCE, NEUROLOGY OR PSYCHIATRY - REVIEW ARTICLE Evidence-based treatment of neurogenic orthostatic hypotension
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationThe New England Journal of Medicine SYMPATHETIC CARDIONEUROPATHY IN DYSAUTONOMIAS
SYMPATHETIC CARDIONEUROPATHY IN DYSAUTONOMIAS DAVID S. GOLDSTEIN, M.D., PH.D., COURTNEY HOLMES, C.M.T., RICHARD O. CANNON III, M.D., GRAEME EISENHOFER, PH.D., AND IRWIN J. KOPIN, M.D. ABSTRACT Background
More informationThe Legacy of Dr. David Robertson Diagnosis and Treatment of Autonomic Disorders
The Legacy of Dr. David Robertson Diagnosis and Treatment of Autonomic Disorders May 3-4, 2018 David Robertson, M.D. Elton Yates Professor of Medicine, Pharmacology & Neurology Vanderbilt University Medical
More informationmetabolism inhibition, this approach causes other adverse effects. The dosage of L-dopa can be brought down further by co-medication of dopamine
6XPPDU\ Parkinson s disease is a serious neurological disorder of the central nervous system that usually becomes apparent after the age of 55. It concerns the increased deterioration of neurons responsible
More informationProgression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment
European Journal of Neurology 2007, 14: 66 72 doi:10.1111/j.1468-1331.2006.01554.x Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment M. Köllensperger
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationRecognition and Management of Orthostatic Hypotension in Primary Care
Recognition and Management of Orthostatic Hypotension in Primary Care Jennifer Jones, MD; Louis Kuritzky, MD CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES Classify patients by type of orthostatic hypotension
More informationAtypical parkinsonism
Atypical parkinsonism Wassilios Meissner Service de neurologie et CMR atrophie multisystématisée, CHU de Bordeaux Institut des Maladies Neurodégénératives, Université Bordeaux 2, CNRS UMR 5293 Parkinsonism?
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationHypertension and Cholesterol in the Elderly
Hypertension and Cholesterol in the Elderly Angela Sanford, MD Assistant Professor of Geriatrics Saint Louis University School of Medicine I have no relevant financial disclosures Cushman WC. The burden
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationGanglionic Blockers. Ganglion- blocking agents competitively block the action of
Ganglionic Blockers Ganglion- blocking agents competitively block the action of acetylcholine and similar agonists at nicotinic (Nn) receptors of both parasympathetic and sympathetic autonomic ganglia.
More informationJune 8, 2018, London UK TREATMENT OF VASOVAGAL SYNCOPE
June 8, 2018, London UK TREATMENT OF VASOVAGAL SYNCOPE Where to go for help Syncope: HRS Definition Syncope is defined as: a transient loss of consciousness, associated with an inability to maintain postural
More informationJournal of the American College of Cardiology Vol. 37, No. 1, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01062-7 Autonomic
More informationFaculty Disclosure. Sanjay P. Singh, MD, FAAN. Dr. Singh has listed an affiliation with: Consultant Sun Pharma Speaker s Bureau Lundbeck, Sunovion
Faculty Disclosure Sanjay P. Singh, MD, FAAN Dr. Singh has listed an affiliation with: Consultant Sun Pharma Speaker s Bureau Lundbeck, Sunovion however, no conflict of interest exists for this conference.
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationNeurogenic orthostatic hypotension: the very basics
Clin Auton Res (2017) 27:39 43 DOI 10.1007/s10286-017-0437-3 EDITORIAL Neurogenic orthostatic hypotension: the very basics Horacio Kaufmann 1 Jose-Alberto Palma 1 Received: 7 June 2017 / Accepted: 8 June
More informationHow to manage a patient with orthostatic hypotension
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 13 How to manage a patient with autonomic dysfunction - Level 2 How to manage a patient with
More informationSYNCOPE. Sanjay P. Singh, MD Chairman & Professor, Department of Neurology. Syncope
SYNCOPE Sanjay P. Singh, MD Chairman & Professor, Department of Neurology. Syncope Syncope is a clinical syndrome characterized by transient loss of consciousness (TLOC) and postural tone that is most
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationThe mechanisms that maintain water and electrolyte homeostasis
The Pressor Response to Water Drinking in Humans A Sympathetic Reflex? Jens Jordan, MD; John R. Shannon, MD; Bonnie K. Black, BSN; Yasmine Ali, BS; Mary Farley; Fernando Costa, MD; Andre Diedrich, MD;
More informationOrthostatic Hypotension (Postural Hypotension)
Orthostatic Hypotension (Postural Hypotension) Authors: SCIRE Community Team Reviewed by: Darryl Caves, PT Last updated: April 9, 2018 Changes to blood pressure control after spinal cord injury (SCI) may
More informationContemporary Management of Spinal Cord Injury
Contemporary Management of Spinal Cord Injury Ali Salim, MD Professor of Surgery Chief, Division of Trauma, Burns, Surgical Critical Care, and Emergency General Surgery Disclosures I have nothing to disclose
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationPa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006
Pathways bolt 16/6/06 20:38 Page 1 Pa t h w a y s A PARADIGM FOR DISEASE MANAGEMENT IN Pa r k i n s o n s Disease MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Clinical diagnosis Pa r k i n s o n s disease
More informationPyridostigmine in the Treatment of Postural Orthostatic Tachycardia: A Single-Center Experience
Pyridostigmine in the Treatment of Postural Orthostatic Tachycardia: A Single-Center Experience KHALIL KANJWAL, M.D.,* BEVERLY KARABIN, PH.D.,* MUJEEB SHEIKH, M.D.,* LAWRENCE ELMER, M.D., PH.D., YOUSUF
More informationMultiple System Atrophy
Multiple System Atrophy This document has been prepared to help you become more informed about Multiple System Atrophy. It is designed to answer questions about the condition and includes suggestions on
More informationNIH Public Access Author Manuscript Lancet Neurol. Author manuscript; available in PMC 2009 January 16.
NIH Public Access Author Manuscript Published in final edited form as: Lancet Neurol. 2008 May ; 7(5): 451 458. doi:10.1016/s1474-4422(08)70088-7. Update on Management of Neurogenic Orthostatic Hypotension
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationABSTRACT PLAIN LANGUAGE SUMMARY
https://doi.org/10.1007/s40119-018-0124-z CASE REPORT Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and
More informationOrthostatic Hypotension
Orthostatic Hypotension http://suntechmed.web4.hubspot.com/portals/41365/images/bloodpressuredoctor.jpg Orthostatic (postural) hypotension is an excessive fall in BP when an upright position is assumed.
More informationLU:research Institutional Repository of Lund University
LU:research Institutional Repository of Lund University This is an author produced version of a paper published in International journal of geriatric psychiatry. This paper has been peer-reviewed but does
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationCompression therapy in patients with orthostatic hypotension: a systematic review
REVIEW Compression therapy in patients with orthostatic hypotension: a systematic review H.E. Smeenk 1 *, M.J. Koster 1, R.A. Faaij 1, D.B. de Geer 2, M.E. Hamaker 1 1 Department of Geriatric Medicine,
More informationIntegrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 3 Pharmacology of the Autonomic Nervous System Multimedia Directory Slide 19 Slide 37 Slide 38 Slide 39 Slide 40 Slide 41 Slide 42 Slide 43
More informationComparison of the Assessment of Orthostatic Hypotension Using Peripheral and Central Blood Pressure Measurements
Original Article J Clin Med Res. 2018;10(4):309-313 Comparison of the Assessment of Orthostatic Hypotension Using Peripheral and Central Blood Pressure Measurements Kannayiram Alagiakrishnan a, d, Ruojin
More informationThe Systemic Effect Of Topical Timolol On Some Cardiovascular Parameters In Owerri Municipality
ISPUB.COM The Internet Journal of Third World Medicine Volume 5 Number 1 The Systemic Effect Of Topical Timolol On Some Cardiovascular Parameters In Owerri Municipality G Oze, M Emegwamuo, P Eleanya, H
More informationOrthostatic Hypotension Following Spinal Cord Injury
Orthostatic Hypotension Following Spinal Cord Injury Andrei Krassioukov, MD, PhD, FRCPC Jill Maria Wecht, EdD Robert W Teasell, MD, FRCPC Janice J Eng, PhD, BSc (PT/OT) www.scireproject.com Version 5.0
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationDepartment of Paediatrics Clinical Guideline. Syncope Guideline
Department of Paediatrics Clinical Guideline Syncope Guideline Definition Transient, self-limited loss of consciousness (TLOC), usually leading to falling. Onset is relatively rapid. Recovery is spontaneous,
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationwho have been unresponsive to L-dopa therapy
Journal of Neurology, Neurosurgery, and Psychiatry, 1973, 36, 362-367 An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy ROBERT J. MONES From the Mt. Sinai
More informationJoint Session with ACOFP and Mayo Clinic. Parkinson's Disease: 5 Pearls. Jay Van Gerpen, MD
Joint Session with ACOFP and Mayo Clinic Parkinson's Disease: 5 Pearls Jay Van Gerpen, MD Parkinson s Disease: 5 Pearls J.A. van Gerpen, MD Sections of Movement Disorders and Clinical Neurophysiology
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationMULTI SYSTEM ATROPHY: REPORT OF TWO CASES Dipu Bhuyan 1, Rohit Kr. Chandak 2, Pankaj Kr. Patel 3, Sushant Agarwal 4, Debjanee Phukan 5
MULTI SYSTEM ATROPHY: REPORT OF TWO CASES Dipu Bhuyan 1, Rohit Kr. Chandak 2, Pankaj Kr. Patel 3, Sushant Agarwal 4, Debjanee Phukan 5 HOW TO CITE THIS ARTICLE: Dipu Bhuyan, Rohit Kr. Chandak, Pankaj Kr.
More information